HeyJaredDae Lee
- Indexed articles, last 90 days
- 11
- Latest publication
- Sep 16, 2026
- Outlet visibility, for Mondaq
- Top 500K sites
- Earliest in this view
- Jul 23, 2026
Latest articles
Qui Tam Lives To Fight Another Day: What The Eleventh Circuit’s Zafirov Decision Means For The False Claims Act (opens the original)
Read excerpt
The False Claims Act’s qui tam provisions are among the federal government’s most important tools for identifying and pursuing alleged fraud involving Medicare, Medicaid, federal health care programs and other government funds. The statute permits a private individual, known as a relator, to bring a False Claims Act action “for the person and for the United States Government” in the name of the government. 31 U.S.C. § 3730(b)(1). If the action succeeds, the relator may receive a share of the rec
Pharmacy Succession Planning: Navigating Change Of Ownership, Medicare, Medicaid And PBM Requirements (opens the original)
Read excerpt
For pharmacy owners, succession planning involves much more than finding a buyer, negotiating a purchase price and signing a purchase agreement. A pharmacy operates within a complicated network of state licenses, federal and state healthcare programs, pharmacy benefit manager (PBM) contracts, pharmacy services administrative organization (PSAO) relationships, National Provider Identifier (NPI) records, Drug Enforcement Administration (DEA) registrations, accreditations and other payor arrangemen
Restoring DMEPOS Medicare Billing Privileges: Challenging Revocations, Reactivation Dates And Enrollment Determinations (opens the original)
Read excerpt
When Medicare revokes or deactivates a Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) supplier’s billing privileges, getting the supplier back into the Medicare program may be only part of the battle. The effective date of the supplier’s restored billing privileges can be just as important because a gap in Medicare enrollment may prevent the supplier from receiving reimbursement for items and services furnished during the disputed period. A supplier may successfully demo
FDA Advisory Committee Voted Yes On Six Peptides. Now What? The Regulatory Road Ahead (opens the original)
Read excerpt
As previously reported, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) recently voted in favor of adding six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax—to the list of bulk drug substances that may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act (the 503A Bulks List). The July 2026 votes represented a significant development for the compounding industry, particularly because FDA staff had recommended against inclusion of the peptides
Ohio Board of Pharmacy Proposes Expansion of Technology-Enabled Pharmacy Practice (opens the original)
Read excerpt
The Ohio Board of Pharmacy is considering a significant modernization of its rules governing how pharmacy services may be performed, verified and delivered through technology. On August 14, 2026, the Board released a package of eight proposed rules addressing shared pharmacy services, remote prescription processing, central fill, electronic product verification, automated pharmacy systems, automated drug storage systems and self-service prescription kiosks. Stakeholder comments are due September
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Mondaq, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.